Literature DB >> 10907770

Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.

J Robert1, D Trystram, C Truffot-Pernot, B Carbonnelle, J Grosset.   

Abstract

OBJECTIVE: To measure the rate of primary and secondary drug resistance of Mycobacterium tuberculosis on an ongoing basis.
DESIGN: Data on all culture-positive tuberculosis were collected prospectively from 1995 through 1997 from a microbiological laboratory network of 19 university hospitals throughout France, and submitted quarterly to the National Reference Centre for Surveillance of Mycobacterial Diseases.
RESULTS: A total of 2998 patients were included in the study. Among the 2333 (78%) previously untreated patients, 8.6% had isolates resistant to any drug, 4.8% to streptomycin (SM) alone, 1.2% to isoniazid (INH) alone, 1.8% to SM + INH, and 0.3% to INH + rifampicin (RMP) or multidrug resistance (MDR). Foreign birth was independently associated with a higher risk of primary resistance to any drug (odds ratio [OR] 1.5). Among the 268 (9%) previously treated patients, 20.9% had isolates resistant to any drug, 6.3% to SM alone, 3.4% to INH alone, 4.1% to SM + INH, and 3.7% to INH + RMP. Foreign birth (OR = 2.3), and human immunodeficiency virus positive status (OR = 4.4) were independently associated with a higher risk of secondary resistance to any drug.
CONCLUSION: During the last 30 years there has been no increase in resistance to any drug among previously untreated patients. As expected, secondary resistance was highly associated with foreign birth. MDR-TB remains a rare event in France.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10907770

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001-2002.

Authors:  E Guerrin-Tran; J-M Thiolet; C Rousseau; S Henry; C Poirier; D Che; J-M Vinas; V Jarlier; J Robert
Journal:  Eur J Epidemiol       Date:  2006-11-15       Impact factor: 8.082

2.  Tuberculosis drug resistance in Canada, 1998 to 2000.

Authors:  M D Phypers; L Panaro; P Nault
Journal:  Can J Infect Dis       Date:  2001-05

Review 3.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

4.  Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004.

Authors:  P M Khuê; A Mallet; N Veziris; V Jarlier; J Robert
Journal:  Epidemiol Infect       Date:  2007-11-21       Impact factor: 2.451

5.  Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study.

Authors:  Abdulhalik Workicho; Wondwosen Kassahun; Fessahaye Alemseged
Journal:  Infect Drug Resist       Date:  2017-03-13       Impact factor: 4.003

Review 6.  Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review.

Authors:  Sujit Suchindran; Emily S Brouwer; Annelies Van Rie
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.